title: Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.
abstract: Psoriasis (Ps) is a chronic inflammatory disease with an important genetic component. It shares pathophysiological mechanisms with other autoimmune diseases such as psoriatic arthritis (PsA), rheumatoid arthritis (RA) and Crohn's disease (CD). These conditions can be treated using biological drugs such as infliximab, adalimumab and etanercept, which selectively block the proinflammatory cytokine tumor necrosis factor (TNF)-α. Although these agents have greatly improved the prognosis of Ps, PsA, RA and CD, they do not cure the disease and are expensive; in addition, significant proportions of patients do not respond or develop serious adverse effects. Therefore, it is important to investigate biomarkers, such as gene polymorphisms, that can predict which patients will respond best to a specific drug. Some polymorphisms in genes TNF, TNF receptor superfamily 1B (TNFR1B) and TNFα-induced protein 3 gene (TNFAIP3) have been associated with response to anti-TNF therapy in patients with Ps. The present article reviews other polymorphisms that could also play a role in prediction of response to these treatments.
authors: Service of Clinical Pharmacology, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain. rociomaria.prieto@salud.madrid.org
authors: R
authors: R
authors: Prieto-Pérez
authors: T
authors: T
authors: Cabaleiro
authors: E
authors: E
authors: Daudén
authors: F
authors: F
authors: Abad-Santos
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000235:genetics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics*; D054316:Biomarkers, Pharmacological; D003424:Crohn Disease / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000069285:Infliximab; D011110:Polymorphism, Genetic; D011379:Prognosis; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D054316:Biomarkers, Pharmacological; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab